Raymond T. Keane
Nessuna posizione attualmente
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Nadim Ahmed | M | 56 | 3 anni | |
| Sandra Leung | F | 63 | 32 anni | |
| Stephen Webster | M | 63 | 4 anni | |
| Anne-Marie Martin | M | 52 | 2 anni | |
| Kimberly McCutcheon Jablonski | F | - | 21 anni | |
| Jeffrey Jones | M | 53 | 2 anni | |
| William Perhacs | M | - | 17 anni | |
| Tim Power | M | - | 18 anni | |
| Jay Smith | M | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 11 anni |
| Robert Kerrey | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 anni |
| Jay Skyler | M | 77 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 anni |
| Sunita Zalani | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 10 anni |
| Kevin Johnston | M | - | 2 anni | |
| Stephen Andre | M | 62 | 2 anni | |
| Patrick Hugh Conway | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 anni |
| Chad Messer | M | - | 2 anni | |
| Rose Weldon | F | - | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Giovanni Caforio | M | 59 | 24 anni | |
| Owen Hughes | M | 49 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 8 anni |
| Lamberto Andreotti | M | 73 | 19 anni | |
| Maria E. Cantor | F | 56 | - | |
| Peter R. Dolan | M | 68 | 18 anni | |
| James Cornelius | M | 81 | 10 anni | |
| Charles A. Heimbold | M | - | 20 anni | |
| James Ahlers | M | 59 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 17 anni |
| Daniel M. Bollag | M | 63 | 11 anni | |
| Matthew Ros | M | 57 | 20 anni | |
| Togo Dennis West | M | 81 | 10 anni | |
| Mark W. Durand | M | 64 | 17 anni | |
| Wayne L. Wilson | M | 75 | 8 anni | |
| Gerald Bruce | M | 68 | 8 anni | |
| Robert Whelan | M | 72 | 4 anni | |
| David J. Helfgott | M | - | - | |
| John E. Elicker | M | 64 | 20 anni | |
| Priya Jambhekar | F | - | 3 anni | |
| Steven B. Ratoff | M | 81 | 16 anni | |
| Massimo Radaelli | M | 65 | 8 anni | |
| Douglas Manion | M | 64 | 11 anni | |
| A. Collier Smyth | M | 78 | 15 anni | |
| Rosemary Crane | F | 64 | 20 anni | |
| Fouad Namouni | M | 55 | 21 anni | |
| Jon Wigginton | M | 62 | 2 anni | |
| Michael Williams | M | - |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 1 anni |
| Jason Haddock | M | 54 | 14 anni | |
| David Spellman | M | 48 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 1 anni |
| John Tsai | M | 57 | 11 anni | |
| Jeffrey Trigilio | M | 40 | 4 anni | |
| Joseph Squicciarino | M | 67 | 22 anni | |
| Brian Daniels | M | 65 | 14 anni | |
| Timothy Meeker | M | 77 | 13 anni | |
| Robert Williams | M | 75 | 7 anni | |
| Michael Grobstein | M | 81 | 13 anni | |
| Alan J. Lacy | M | 70 | 12 anni | |
| Louis Gerstner | M | - | - | |
| Barry J. Wolfenson | M | 57 | 23 anni | |
| Charles Sigal | M | 72 | 16 anni | |
| Laurie Glimcher | M | 72 | 20 anni | |
| Lewis B. Campbell | M | 77 | 18 anni | |
| James Robinson | M | 88 | 29 anni | |
| Leif Valdemar Johansson | M | 73 | 13 anni | |
| Vicki Sato | M | 75 | 15 anni | |
| Anthony Hooper | M | 69 | 15 anni | |
| Louis J. Freeh | M | 74 | 8 anni | |
| Laurie A. Allen | F | 63 | 9 anni | |
| Norbert Riedel | M | 66 | 6 anni | |
| Harrison Bains | M | 80 | 16 anni | |
| Lawrence Hamilton | M | 66 | 8 anni | |
| Robert Berman | M | 61 | 10 anni | |
| William T. Comer | M | 85 | 9 anni | |
| Vladimir Coric | M | 53 | 8 anni | |
| Michael Loberg | M | 76 | 18 anni | |
| John Shamsey | M | - | 6 anni | |
| Catherine Knupp | M | 63 | 14 anni | |
| Dolca Thomas | M | 53 | 4 anni | |
| Luisa Salter-Cid | M | 60 | 13 anni | |
| Robert E. Allen | M | - | 21 anni | |
| J. Brian Stalter | M | 52 | 11 anni | |
| Steve Innaimo | M | - | 23 anni | |
| James Daniel Guylain Priour | M | 57 | - | |
| Mark Neumann | M | 61 | 26 anni | |
| Kenton L. Shultis | M | 68 | 9 anni | |
| Rachel Humphrey | M | 62 | 9 anni | |
| David J. Franklin | M | - | - | |
| R. Jean-Marc Sidney Huët | M | 55 | 1 anni | |
| Nancy Lurker | F | 66 | 14 anni | |
| Brian M. Gallagher | M | 76 | - | |
| Philippe Deschamps | M | 62 | 12 anni | |
| George Zavoico | M | - | - | |
| Dinesh Patel | M | 67 | 8 anni | |
| Charles Rowland | M | 65 | 8 anni | |
| Stacey M. Lituchy | F | - | - | |
| John F. Bedard | M | 74 | - | |
| Julie Smith | F | 53 | - | |
| Richard L. Wolgemuth | M | 78 | - | |
| Adeoye Olukotun | M | 79 | 13 anni | |
| Marcel Giguère | M | - | 7 anni | |
| Carlo de Notaristefani | M | 67 | 7 anni | |
| Michelle Werner | F | 48 | 10 anni | |
| Paul von Autenried | M | 62 | 26 anni | |
| Allison Luo | M | 50 | 8 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Raymond T. Keane
- Contatti personali
